Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 21;289(8):4553-4.
doi: 10.1074/jbc.R113.543652. Epub 2013 Dec 20.

Introduction to thematic minireview series: Development of human therapeutics based on induced pluripotent stem cell (iPSC) technology

Mahendra Rao  1 , Joel M Gottesfeld
Affiliations

Introduction to thematic minireview series: Development of human therapeutics based on induced pluripotent stem cell (iPSC) technology

Mahendra Rao et al. J Biol Chem. .

Abstract

With the advent of human induced pluripotent stem cell (hiPSC) technology, it is now possible to derive patient-specific cell lines that are of great potential in both basic research and the development of new therapeutics for human diseases. Not only do hiPSCs offer unprecedented opportunities to study cellular differentiation and model human diseases, but the differentiated cell types obtained from iPSCs may become therapeutics themselves. These cells can also be used in the screening of therapeutics and in toxicology assays for potential liabilities of therapeutic agents. The remarkable achievement of transcription factor reprogramming to generate iPSCs was recognized by the award of the Nobel Prize in Medicine to Shinya Yamanaka in 2012, just 6 years after the first publication of reprogramming methods to generate hiPSCs (Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007) Cell 131, 861-872). This minireview series highlights both the promises and challenges of using iPSC technology for disease modeling, drug screening, and the development of stem cell therapeutics.

Keywords: Gene Correction; Genomic Instability; Immunogenicity; Induced Pluripotent Stem Cells; Regenerative Medicine; Stem Cells; Toxicology.

PubMed Disclaimer

References

    1. Kolaja K. (2014) Stem cells and stem cell-derived tissues and their use in safety assessment. J. Biol. Chem. 289, 10.1074/jbc.R113.481028 - DOI - PMC - PubMed
    1. Engle S. J., Vincent F. (2014) Small molecule screening in human induced pluripotent stem cell-derived terminal cell types. J. Biol. Chem. 289, 10.1074/jbc.R113.529156 - DOI - PMC - PubMed
    1. Scheiner Z. S., Talib S., Feigal E. G. (2014) The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies. J. Biol. Chem. 289, 10.1074/jbc.R113.509588 - DOI - PMC - PubMed
    1. Peterson S. E., Loring J. F. (2014) Genomic instability in pluripotent stem cells: implications for clinical applications. J. Biol. Chem. 289, 10.1074/jbc.R113.516419 - DOI - PMC - PubMed
    1. Harding J., Mirochnitchenko O. (2014) Preclinical studies for induced pluripotent stem cell-based therapeutics. J. Biol. Chem. 289, 10.1074/jbc.R113.463737 - DOI - PMC - PubMed

Publication types

MeSH terms